ID: ALA525055

Max Phase: Preclinical

Molecular Formula: C88H144N24O21

Molecular Weight: 1874.27

Molecule Type: Protein

Representations

Canonical SMILES:  CNCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)[C@@H](C)O

Standard InChI:  InChI=1S/C88H144N24O21/c1-48(2)37-62(77(122)98-46-73(119)112-36-20-27-69(112)87(132)105-61(26-15-19-35-92)80(125)104-60(25-14-18-34-91)79(124)103-59(24-13-17-33-90)78(123)102-58(75(94)120)23-12-16-32-89)106-81(126)63(38-49(3)4)107-83(128)65(40-53-28-30-55(115)31-29-53)100-72(118)45-97-76(121)51(7)99-86(131)68(47-113)110-84(129)67(42-70(93)116)108-82(127)64(39-50(5)6)109-88(133)74(52(8)114)111-85(130)66(101-71(117)44-95-9)41-54-43-96-57-22-11-10-21-56(54)57/h10-11,21-22,28-31,43,48-52,58-69,74,95-96,113-115H,12-20,23-27,32-42,44-47,89-92H2,1-9H3,(H2,93,116)(H2,94,120)(H,97,121)(H,98,122)(H,99,131)(H,100,118)(H,101,117)(H,102,123)(H,103,124)(H,104,125)(H,105,132)(H,106,126)(H,107,128)(H,108,127)(H,109,133)(H,110,129)(H,111,130)/t51-,52+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,74-/m0/s1

Standard InChI Key:  NJTGSJIMKWTQSD-GFUYWXIVSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Protein

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 1874.27

Molecular Weight (Monoisotopic): 1873.0938

AlogP:

#Rotatable Bonds:

Polar Surface Area:

Molecular Species:

HBA:

HBD:

#RO5 Violations:

HBA (Lipinski):

HBD (Lipinski):

#RO5 Violations (Lipinski):

CX Acidic pKa:

CX Basic pKa:

CX LogP:

CX LogD:

Aromatic Rings:

Heavy Atoms:

QED Weighted:

Np Likeness Score:

References

1. Bulaj G, Green BR, Lee HK, Robertson CR, White K, Zhang L, Sochanska M, Flynn SP, Scholl EA, Pruess TH, Smith MD, White HS..  (2008)  Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities.,  51  (24): [PMID:19053761] [10.1021/jm801088x]

Source

Source(1):

• Scientific Literature